Kineta Presents New Preclinical Data and Phase 1/2 Clinical Trial Design of KVA12.1 at the Tumor Myeloid-Directed Therapies Summit ...Middle East

SEATTLE, June 17, 2022 /PRNewswire/ -- Kineta, Inc. ("Kineta" or the "Company"), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology, announced today that it presented the Phase 1/2 clinical trial design and new preclinical data...

Hence then, the article about kineta presents new preclinical data and phase 1 2 clinical trial design of kva12 1 at the tumor myeloid directed therapies summit was published today ( Friday 17/06/2022 - 12:16 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Kineta Presents New Preclinical Data and Phase 1/2 Clinical Trial Design of KVA12.1 at the Tumor Myeloid-Directed Therapies Summit )

Also on site :

• ‘Beverly Hills Cop’ Star Judge Reinhold Back With Eddie Murphy in Rare Appearance 42 Years After the Film
• Phish’s New Sphere Residency Blows The (Circular) Roof Off The Joint
• Malaysia launches support package for SMEs to combat energy crisis